8-K: CareDx Reports Strong 2025 Revenue Growth, Appoints New CFO

CareDx, Inc. announced its fourth quarter and full year 2025 financial results, reporting significant revenue growth and appointing Keith Kennedy as its new Chief Financial Officer and Chief Operating Officer.

Summary

• Full Year 2025 total revenue reached $380 million, a 14% increase year-over-year.
• Fourth Quarter 2025 revenue was $108 million, up 25% year-over-year.
• Testing services revenue for Q4 2025 increased by 23% to $78 million, with volume up 17% to approximately 53,000 tests.
• Patient and digital solutions revenue grew 47% year-over-year to $16.8 million in Q4 2025, while product revenue increased 17% to $13.3 million.
• GAAP net loss for Q4 2025 was $4 million, a significant decrease from GAAP net income of $88 million in Q4 2024, primarily due to a $96 million litigation accrual reversal in 2024.
• Full Year 2025 GAAP net loss was $21 million, compared to GAAP net income of $53 million in 2024.
• Adjusted EBITDA for Q4 2025 was $7 million, down from $10 million in Q4 2024, and included approximately $7 million in operating expenses for compensation in lieu of equity grants.
• Full Year 2025 adjusted EBITDA increased to $32 million from $28 million in 2024.
• Cash flow from operations was $21.4 million in Q4 2025 and $42 million for the full year 2025.
• The company repurchased $12 million of shares (773,000 shares at $15.79/share) in Q4 2025 and $88 million (5.8 million shares at $15.16/share) for the full year 2025.
• Keith Kennedy has been appointed Chief Financial Officer and Chief Operating Officer, effective February 26, 2026.
• Nathan Smith resigned as Chief Financial Officer for personal reasons, effective February 25, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report. While revenue growth is strong across all segments and the company is making strategic advancements, the significant GAAP net loss for both the quarter and full year, largely due to the absence of a prior year litigation benefit, tempers the overall sentiment. The decline in Q4 adjusted EBITDA is also a concern, despite the full-year improvement.

Positives

• Strong revenue growth: Q4 2025 total revenue increased 25% year-over-year to $108 million, and full year 2025 total revenue increased 14% to $380 million.
• Growth across all segments: Testing services revenue grew 23% in Q4, patient and digital solutions revenue grew 47%, and product revenue grew 17%.
• Increased testing volume: Testing services volume increased 17% in Q4 2025 and 14% for the full year 2025.
• Positive cash flow from operations: $21.4 million in Q4 2025 and $42 million for the full year 2025.
• Share repurchase program: Repurchased $12 million in Q4 2025 and $88 million for the full year 2025, demonstrating commitment to shareholder returns.
• Strategic business advancements: Published SHORE registry manuscript, advanced Epic Aura integrations (7 live, ~20 underway), launched ImmuneScape multiomics platform, and announced pivotal validation data for AlloHeme.
• Improved full year Adjusted EBITDA: Increased to $32 million in 2025 from $28 million in 2024.
• Non-GAAP net income for full year 2025 increased to $32 million from $31 million in 2024.

Negatives

• Significant GAAP net loss: Q4 2025 GAAP net loss was $4 million, a substantial decline from GAAP net income of $88 million in Q4 2024.
• Full year 2025 GAAP net loss was $21 million, compared to GAAP net income of $53 million in 2024.
• Adjusted EBITDA decline in Q4: Q4 2025 adjusted EBITDA decreased to $7 million from $10 million in Q4 2024, partly due to $7 million in operating expenses for compensation in lieu of equity grants.
• The prior year's GAAP net income was significantly boosted by a $96 million litigation accrual reversal, making the current year's GAAP performance appear worse by comparison.

Risks

• General economic and market factors.
• Global economic and marketplace uncertainties.
• Risks discussed in the company's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• Estimated 6-month impact of the Medicare LCD of approximately $7.5 million on 2026 revenue.

Future Outlook

CareDx expects full year 2026 revenue to be in the range of $420 million to $444 million, which accounts for an estimated $7.5 million impact from the Medicare LCD over six months. The company also projects full year 2026 adjusted EBITDA to be between $30 million and $45 million, indicating anticipated continued profitability and operational efficiency.

Management Comments

• "We delivered a strong finish to 2025, reflecting disciplined execution across the business and continued momentum in our core testing services, patient and digital solutions, and lab products."
• "As we enter 2026, we believe we are well positioned to build on this momentum and continue delivering meaningful value for transplant patients, clinicians, and shareholders."

Industry Context

StockSavvy.ai notes that CareDx operates in the specialized and growing precision medicine sector for transplant patients, a market driven by increasing demand for personalized diagnostics and improved patient outcomes. The company's focus on noninvasive molecular testing and digital health technologies aligns with broader industry trends towards less invasive diagnostics and integrated care platforms. The strategic collaboration with 10x Genomics for ImmuneScape and the advancement of AlloHeme indicate a commitment to innovation and expansion into new areas like cell therapy, positioning CareDx to potentially capture additional market share in a competitive landscape that includes other diagnostic companies and research institutions. The integration with Epic Aura also highlights a move towards better workflow integration, a key differentiator in healthcare IT.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark CareDx's performance against global industry standards. Therefore, a direct comparison is not possible based solely on the provided information.

Management Changes

Corporate Governance

Legal Proceedings

• The 2024 GAAP net income included a $96 million reversal of a litigation accrual associated with damages related to the alleged infringement of patent '544 accrued in 2023. This is a past event that positively impacted 2024 results, not a current proceeding.

Related Party Transactions

• No reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Mr. Kennedy.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, share repurchases, and strategic advancements. Negative impact from GAAP net losses and Q4 adjusted EBITDA decline.
• Employees: Transition in key leadership roles with the appointment of a new CFO/COO.
• Customers (Transplant Patients/Clinicians): Continued development and integration of precision medicine solutions (HeartCare, Epic Aura, ImmuneScape, AlloHeme) aim to improve patient outcomes and workflow efficiency.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned, but positive cash flow and cash position are generally favorable.

Next Steps

• Filing of the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC on February 25, 2026.
• Filing of the Release Agreement with Nathan Smith as an exhibit to the Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2026.
• Continued building on momentum in core testing services, patient and digital solutions, and lab products in 2026.
• Further Epic Aura integrations, with approximately twenty implementations underway.
• Advancing CareDx's expansion beyond solid organ transplantation into cell therapy and hematologic malignancies with AlloHeme.

Key Dates

Recommendation

The company demonstrates strong top-line growth and strategic advancements in its precision medicine offerings, which are positive indicators for long-term potential. However, the significant GAAP net losses for both the quarter and full year, even when accounting for the prior year's litigation accrual reversal, and the decline in Q4 adjusted EBITDA, present a mixed financial picture. The new CFO appointment brings extensive experience, which is a positive, but the immediate financial performance on a GAAP basis warrants caution. Investors should hold to observe if the company can translate its revenue growth into consistent GAAP profitability and improved adjusted EBITDA margins in future periods, especially given the anticipated impact of the Medicare LCD.

Keywords

CareDx, CDNA, Transplant Company, Precision Medicine, Financial Results, Q4 2025, Full Year 2025, 2026 Guidance, Revenue Growth, Testing Services, Patient Solutions, Digital Solutions, Product Revenue, GAAP Net Loss, Adjusted EBITDA, CFO Appointment, Keith Kennedy, Nathan Smith, Share Repurchase, Organ Health, Molecular Testing, Epic Aura, ImmuneScape, AlloHeme, SEC Filing, 8-K